Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.48, while State Street SPDR S&P Biotech ETF trades at $153.65. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $26.59 | $164.28 |
52-Week Low | $24.83 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.47, showing minimal daily movement with a slight decline of 0.04%. Technical indicators signal a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. The ETF maintains consistent dividend payments of $0.14 per share throughout 2026, providing steady income. Recent news highlights growing institutional interest in emerging market bonds as investors seek yield above Treasury rates.
The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market debt's attractive yield premium. However, currency risk and capital erosion concerns persist as short interest has surged 73%, indicating skepticism about long-term sustainability despite the 6.1% trailing yield.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
